Penumbra, Inc. (NYSE: PEN) changed 2.57% to recent value of $142. The stock transacted 327654 shares during most recent day however it has an average volume of 366.62K shares. It spotted trading -15.15% off 52-week high price. On the other end, the stock has been noted 59.91% away from the low price over the last 52-weeks.
Penumbra, Inc. (NYSE: PEN) notified that two new Board members were appointed to its Board of Directors (the “Board”) on January 17, 2019. Ms. Janet Leeds was appointed to the Board as a Class I director, effective immediately, and Ms. Surbhi Sarna was appointed to the Board as a Class II director, effective July 1, 2019. With the addition of these two directors, the Penumbra Board will be comprised of eight directors, six of whom are independent.
“We are thrilled to welcome Janet and Surbhi to our Board. Both of these individuals will bring added experience, perspective, and capability to our Board of Directors which will be invaluable as we continue to grow and scale our company. Janet brings to the Board a strong healthcare background with experience in organizational development and governance. Surbhi brings new capabilities that will complement the skills of our existing Board and additional perspective to advise on topics that are important to innovation and our future growth. The addition of Janet and Surbhi will greatly benefit the Board and management team at Penumbra, and I look forward to their help and counsel as we continue our mission to positively impact many more patients and families in the future,” said Adam Elsesser, Chairman, Chief Executive Officer and President.
Ms. Leeds has held a number of leadership and consulting roles in academic healthcare settings over more than thirty years. Currently, Ms. Leeds serves as an Administrative Director at the Seattle Cancer Care Alliance (“SCCA”), a cancer center comprising Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital and UW Medicine. From 2005 to 2009, Ms. Leeds served as the Administrator for the Fred Hutchinson/University of Washington Cancer Consortium. From 2000 to 2005, Ms. Leeds served as the Director of Planning at the Fred Hutchinson Cancer Research Center. From 1996 to 2000, Ms. Leeds served in various positions that were instrumental to the formation and development of the SCCA. Prior to that, from 1987 to 1995, Ms. Leeds held management consultant positions of increasing responsibility at ECG Management Consultants, where she primarily consulted with academic medical centers. Ms. Leeds received a BA from Stanford University and an MBA from the University of Washington.
PEN has a gross margin of 66.10% and an operating margin of -0.90% while its profit margin remained 2.10% for the last 12 months. Its earnings per share (EPS) expected to touch remained 43.70% for this year while earning per share for the next 5-years is expected to reach at 20.00%.
The company has 33.64M of outstanding shares and 32.23M shares were floated in the market. According to the most recent quarter its current ratio was 6.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 14.27% from the mean of 20 days, 9.05% from mean of 50 days SMA and performed 2.64% from mean of 200 days price. Company’s performance for the week was 11.94%, 17.43% for month and YTD performance remained 16.20%.